@conference{6bf2849ca84c4ab0819c0439ef97c494,
title = "Preclinical study of cytotoxicity and predictive markers of response to dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 with or without paclitaxel or nab-paclitaxel as a new therapeutic strategy in pancreatic cancer cell lines",
author = "\{Guardiola Amado\}, \{Victor D\}",
note = "e15007 Background: Targeting the phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) (PI3K-AKT-mTOR) pathway could arrest tumor growth and induce cell death in cancers that are resistant to currently available therapies. NVP-BEZ235 is an oral, targeted anticancer agent which exerts its potential activity through PI3K/mTOR dual inhibition.; American Society of Clinical Oncology (ASCO) Annual Meeting ; Conference date: 01-01-2014",
year = "2013",
language = "American English",
}